Artiva Biotherapeutics estimates wind-down charges of $27 million to $35 million
ARTV•Artiva Biotherapeutics estimates wind-down costs of $27 million to $35 million, including $10 million to $15 million in contract termination and clinical trial closeout costs and $17 million to $20 million in workforce reduction costs.
1. Wind-down estimates
Artiva Biotherapeutics expects to cut approximately 94% of its employees, with workforce reductions completed in the first quarter of 2027. Most wind-down costs are expected in the fourth quarter of 2026. The wind-down follows the decision to discontinue AlloNK development while exploring strategic alternatives to maximize stockholder value.
